A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight

Interventions

DRUG: Bimagrumab
DRUG: Tirzepatide
DRUG: Bimagrumab Placebo
DRUG: Tirzepatide Placebo

Sponsor

Eli Lilly and Company